NCT07428616

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-05-21Est. Completion: 2028-02-29

Enrollment target: 100 participants

Locations

University of Alabama, Birmingham, Alabama, United States
Mayo Clinic_Arizona, Phoenix, Arizona, United States
University of California, San Francisco, San Francisco, California, United States
Providence - Saint John's Health Center, Santa Monica, California, United States
Mayo Clinic_Jacksonville, Jacksonville, Florida, United States
Baptist Health Miami Cancer Institute, Miami, Florida, United States
Tampa General Hospital, Tampa, Florida, United States
Northwestern University, Chicago, Illinois, United States
LSU Health Science Center, New Orleans, Louisiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Mayo Clinic_Rochester, Rochester, New York, United States
Duke University, Durham, North Carolina, United States
The Ohio State University College of Medicine (OSUCOM), Columbus, Ohio, United States

High Grade MeningiomaEpendymomaMedulloblastomaPNETPrimary CNS Sarcoma

Background: Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, ac…

Bethesda, United StatesCompleted May 6, 2025

Malignant TumorBenign NeoplasmParkinson DiseaseTrigeminal NeuralgiaArteriovenous Malformations

This retrospective observational study aims to evaluate the efficacy and toxicity of advanced radiotherapy (ART) techniq…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.